Species differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirus

Molecular Pharmaceutics

Volumn 8, Issue 1, 2011, Pages 78-92

  Wonganan, Piyanuch ^a   Clemens, Courtney C ^a   Brasky, Kathy ^b   Pastore, Lucio ^c   Croyle, Maria A ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b SOUTHWEST NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Adenovirus; Non human primate; PEGylation; Pharmacokinetics; Toxicology

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; BETA GALACTOSIDASE; BILIRUBIN; CYTOCHROME P450 3A2; CYTOCHROME P450 3A4; D DIMER; INTERLEUKIN 12; INTERLEUKIN 6; LACTATE DEHYDROGENASE; PEGYLATED HELPER DEPENDENT ADENOVIRUS VECTOR; SERUM ALBUMIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BABOON; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; ENZYME ACTIVITY; HEART; HELPER VIRUS; KIDNEY; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LEUKOCYTE DIFFERENTIAL COUNT; LIVER; LIVER METABOLISM; LUNG; MALE; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PEGYLATION; PLASMA CLEARANCE; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPECIES DIFFERENCE; SPLEEN; THROMBOCYTOPENIA;

ADENOVIRIDAE; ANIMALS; BLOTTING, SOUTHERN; BLOTTING, WESTERN; LIVER; MALE; MICE; PAPIO; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; TRANSDUCTION, GENETIC;

EID: 79952983088     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100216h     Document Type: Article

References (81)

1. Buller, R. E.; Runnebaum, I. B.; Karlan, B. Y.; Horowitz, J. A.; Shahin, M.; Buekers, T.; Petrauskas, S.; Kreienberg, R.; Slamon, D.; Pegram, M. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 2002, 9 (7), 553-66. (Pubitemid 34734419)
2. Abuchowski, A.; McCoy, J. R.; Palczuk, N. C.; van Es, T.; Davis, F. F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 1977, 252 (11), 3582-6. (Pubitemid 8116088)
3. Abuchowski, A.; van Es, T.; Palczuk, N. C.; Davis, F. F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 1977, 252 (11), 3578-81. (Pubitemid 8116087)
4. Ryan, S. M.; Mantovani, G.; Wang, X.; Haddleton, D. M.; Brayden, D. J. Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin. Drug DeliVery 2008, 5 (4), 371-83. (Pubitemid 351721718)
5. Veronese, F. M.; Mero, A. The impact of PEGylation on biological therapies. BioDrugs 2008, 22 (5), 315-29.
6. Fishburn, C. S. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J. Pharm. Sci. 2008, 97 (10), 4167-83.
7. Jain, A.; Jain, S. K. PEGylation: an approach for drug delivery. A review. Crit. ReV. Ther. Drug Carrier Syst. 2008, 25 (5), 403-47.
8. Bouard, D.; Alazard-Dany, D.; Cosset, F. L. Viral vectors: from virology to transgene expression. Br. J. Pharmacol. 2009, 157 (2), 153-65.
9. Schaffer, D. V.; Koerber, J. T.; Lim, K. I. Molecular engineering of viral gene delivery vehicles. Annu. ReV. Biomed. Eng. 2008, 10, 169-94.
10. Kreppel, F.; Kochanek, S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol. Ther. 2008, 16 (1), 16-29.
11. O'Riordan, C. R.; Lachapelle, A.; Delgado, C.; Parkes, V.; Wadsworth, S. C.; Smith, A. E.; Francis, G. E. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 1999, 10 (8), 1349-58. (Pubitemid 29267589)
12. Croyle, M. A.; Yu, Q. C.; Wilson, J. M. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum. Gene Ther. 2000, 11 (12), 1713-22.
13. Croyle, M. A.; Chirmule, N.; Zhang, Y.; Wilson, J. M. Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol. 2001, 75 (10), 4792-801. (Pubitemid 32381522)
14. Croyle, M. A.; Chirmule, N.; Zhang, Y.; Wilson, J. M. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum. Gene Ther. 2002, 13 (15), 1887-900. (Pubitemid 35292683)
15. Croyle, M. A.; Le, H. T.; Linse, K. D.; Cerullo, V.; Toietta, G.; Beaudet, A.; Pastore, L. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther. 2005, 12 (7), 579-87. (Pubitemid 40468105)
16. Mok, H.; Palmer, D. J.; Ng, P.; Barry, M. A. Evaluation of polyethylene glycol modification of first-generation and helperdependent adenoviral vectors to reduce innate immune responses. Mol. Ther. 2005, 11 (1), 66-79. (Pubitemid 40012000)
17. Le, H. T.; Yu, Q. C.; Wilson, J. M.; Croyle, M. A. Utility of PEGylated recombinant adeno-associated viruses for gene transfer. J. Controlled Release 2005, 108 (1), 161-77. (Pubitemid 41476684)
18. Lee, G. K.; Maheshri, N.; Kaspar, B.; Schaffer, D. V. PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. Biotechnol. Bioeng. 2005, 92 (1), 24-34. (Pubitemid 41657584)
19. Croyle, M. A.; Callahan, S. M.; Auricchio, A.; Schumer, G.; Linse, K. D.; Wilson, J. M.; Brunner, L. J.; Kobinger, G. P. PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J. Virol. 2004, 78 (2), 912-21. (Pubitemid 38067612)
20. Alemany, R.; Suzuki, K.; Curiel, D. T. Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 2000, 81 (Part 11), 2605-9.
21. Ogawara, K.; Rots, M. G.; Kok, R. J.; Moorlag, H. E.; Van Loenen, A. M.; Meijer, D. K.; Haisma, H. J.; Molema, G. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum. Gene Ther. 2004, 15 (5), 433-43. (Pubitemid 38639615)
22. Weaver, E. A.; Barry, M. A. Effects of Shielding Adenoviral Vectors with Polyethylene Glycol (PEG) on Vector-specific and Vaccine-mediated Immune Responses. Hum. Gene Ther. 2008, 19 (12), 1369-82.
23. Sakurai, H.; Kawabata, K.; Sakurai, F.; Nakagawa, S.; Mizuguchi, H. Innate immune response induced by gene delivery vectors. Int. J. Pharm. 2008, 354 (12), 9-15. (Pubitemid 351400322)
24. Raty, J. K.; Lesch, H. P.; Wirth, T.; Yla-Herttuala, S. Improving safety of gene therapy. Curr. Drug Saf. 2008, 3 (1), 46-53. (Pubitemid 351223153)
25. Segura, M. M.; Alba, R.; Bosch, A.; Chillon, M. Advances in helper-dependent adenoviral vector research. Curr. Gene Ther. 2008, 8 (4), 222-35.
26. Seiler, M. P.; Cerullo, V.; Lee, B. Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects. Curr. Gene Ther. 2007, 7 (5), 297-305. (Pubitemid 47595772)
27. Brunetti-Pierri, N.; Ng, P. Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors. Gene Ther. 2008, 15 (8), 553-60.
28. Brunetti-Pierri, N.; Palmer, D. J.; Beaudet, A. L.; Carey, K. D.; Finegold, M.; Ng, P. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum. Gene Ther. 2004, 15 (1), 35-46. (Pubitemid 38147187)
29. Raper, S. E.; Chirmule, N.; Lee, F. S.; Wivel, N. A.; Bagg, A.; Gao, G. P.; Wilson, J. M.; Batshaw, M. L. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 2003, 80 (12), 148-58. (Pubitemid 37272241)
30. Morral, N.; O'Neal, W. K.; Rice, K.; Leland, M. M.; Piedra, P. A.; Aguilar-Cordova, E.; Carey, K. D.; Beaudet, A. L.; Langston, C. Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum. Gene Ther. 2002, 13 (1), 143-54. (Pubitemid 34075178)
31. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (1997). Guidance for Industry: S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals.
32. Pugsley, M. K.; Authier, S.; Curtis, M. J. Principles of safety pharmacology. Br. J. Pharmacol. 2008, 154 (7), 1382-99.
33. Bussiere, J. L. Species selection considerations for preclinical toxicology studies for biotherapeutics. Expert Opin. Drug Metab. Toxicol. 2008, 4 (7), 871-7.
34. Qiu, H.; Mathäs, M.; Nestler, S.; Bengel, C.; Nem, D.; Gödtel- Armbrust, U.; Lang, T.; Taudien, S.; Burk, O.; Wojnowski, L. CYP3 phylogenomics: evidence for positive selection of CYP3A4 and CYP3A7. Pharmacogenet. Genomics 2010, 20 (3), 167-178.
35. Qiu, H.; Taudien, S.; Herlyn, H.; Schmitz, J.; Zhou, Y.; Chen, G.; Roberto, R.; Rocchi, M.; Platzer, M.; Wojnowski, L. CYP3 phylogenomics: evidence for positive selection of CYP3A4 and CYP3A7. Pharmacogenet. Genomics 2008, 18 (1), 53-66. (Pubitemid 351161648)
36. Zhou, S. F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab. 2008, 9 (4), 310-22.
37. Zhou, H.; Pastore, L.; Beaudet, A. L. Helper-dependent adenoviral vectors. Methods Enzymol. 2002, 346, 177-98. (Pubitemid 41103138)
38. Maizel, J. V., Jr.; White, D. O.; Scharff, M. D. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 1968, 36 (1), 115-25.
39. Palmer, D. J.; Ng, P. Methods for the production of first generation adenoviral vectors. Methods Mol. Biol. 2008, 433, 55-78.
40. Byrd, L. D. A tethering system for direct measurement of cardiovascular function in the caged baboon. Am. J. Physiol. 1979, 236 (5), H775-9. (Pubitemid 9212802)
41. Schnell, M. A.; Zhang, Y.; Tazelaar, J.; Gao, G. P.; Yu, Q. C.; Qian, R.; Chen, S. J.; Varnavski, A. N.; LeClair, C.; Raper, S. E.; Wilson, J. M. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol. Ther. 2001, 3 (5 Part 1), 708-22. (Pubitemid 32509868)
42. Croyle, M. A.; Roessler, B. J.; Davidson, B. L.; Hilfinger, J. M.; Amidon, G. L. Factors that influence stability of recombinant adenoviral preparations for human gene therapy. Pharm. DeV. Technol. 1998, 3 (3), 373-83. (Pubitemid 28410365)
43. Tardieu, M.; Epstein, R. L.; Weiner, H. Interaction of Viruses with Cell Surface Receptors. Int. Rev. Cytol. 1982, 80, 27-61. (Pubitemid 13175408)
44. Oka, K.; Pastore, L.; Kim, I. H.; Merched, A.; Nomura, S.; Lee, H. J.; Merched-Sauvage, M.; Arden-Riley, C.; Lee, B.; Finegold, M.; Beaudet, A.; Chan, L. Long-term stable correction of lowdensity lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation 2001, 103 (9), 1274-81. (Pubitemid 32221352)
45. Coon, M. J.; van der Hoeven, T. A.; Dahl, S. B.; Haugen, D. A. Two forms of liver microsomal cytochrome P-450, P-450lm2 and P-450LM4 (rabbit liver). Methods Enzymol. 1978, 52, 109-17.
46. van der Hoeven, T. Assay of hepatic microsomal testosterone hydroxylases by high-performance liquid chromatography. Anal. Biochem. 1984, 138 (1), 57-65. (Pubitemid 14146648)
47. Callahan, S. M.; Ming, X.; Lu, S. K.; Brunner, L. J.; Croyle, M. A. Considerations for use of recombinant adenoviral vectors: dose effect on hepatic cytochromes P450. J. Pharmacol. Exp. Ther. 2005, 312 (2), 492-501. (Pubitemid 40189545)
48. Hartman, Z. C.; Appledorn, D. M.; Amalfitano, A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res. 2008, 132 (12), 1-14. (Pubitemid 351232078)
49. Othman, M.; Labelle, A.; Mazzetti, I.; Elbatarny, H. S.; Lillicrap, D. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood 2007, 109 (7), 2832-9. (Pubitemid 46482078)
50. Callahan, S. M.; Wonganan, P.; Obenauer-Kutner, L. J.; Sutjipto, S.; Dekker, J. D.; Croyle, M. A. Controlled inactivation of recombinant viruses with vitamin B(2). J. Virol. Methods 2008, 148 (12), 132-45.
51. Nordenholz, K. E.; Mitchell, A. M.; Kline, J. A. Direct comparison of the diagnostic accuracy of fifty protein biological markers of pulmonary embolism for use in the emergency department. Acad. Emerg. Med. 2008, 15 (9), 795-9.
52. Shorr, A. F.; Thomas, S. J.; Alkins, S. A.; Fitzpatrick, T. M.; Ling, G. S. D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest 2002, 121 (4), 1262-8. (Pubitemid 34280452)
53. Callahan, S. M.; Boquet, M. P.; Ming, X.; Brunner, L. J.; Croyle, M. A. Impact of transgene expression on drug metabolism following systemic adenoviral vector administration. J. Gene Med. 2006, 8 (5), 566-76. (Pubitemid 43827250)
54. Callahan, S. M.; Wonganan, P.; Croyle, M. A. Molecular and macromolecular alterations of recombinant adenoviral vectors do not resolve changes in hepatic drug metabolism during infection. Virol. J. 2008, 5 (1), 111.
55. Gardner, M. B.; Luciw, P. A. Macaque models of human infectious disease. ILAR J. 2008, 49 (2), 220-55.
56. Locher, C. P.; Witt, S. A.; Herndier, B. G.; Tenner-Racz, K.; Racz, P.; Levy, J. A. Baboons as an animal model for human immunodeficiency virus pathogenesis and vaccine development. Immunol. ReV. 2001, 183, 127-40. (Pubitemid 34015444)
57. Rogers, J.; Hixson, J. E. Baboons as an animal model for genetic studies of common human disease. Am. J. Hum. Genet. 1997, 61 (3), 489-93. (Pubitemid 27418388)
58. Brunetti-Pierri, N.; Ng, T.; Iannitti, D. A.; Palmer, D. J.; Beaudet, A. L.; Finegold, M. J.; Carey, K. D.; Cioffi, W. G.; Ng, P. Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent adenoviral vectors into the surgically isolated liver of nonhuman primates. Hum. Gene Ther. 2006, 17 (4), 391-404.
59. Haddad, A.; Davis, M.; Lagman, R. The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer 2007, 15 (3), 251-7. (Pubitemid 46295205)
60. Schaller, M.; Hogaboam, C. M.; Lukacs, N.; Kunkel, S. L. Respiratory viral infections drive chemokine expression and exacerbate the asthmatic response. J. Allergy Clin. Immunol. 2006, 118 (2), 295-302. (Pubitemid 44142727)
61. Seemungal, T. A.; Wedzicha, J. A. Viral infections in obstructive airway diseases. Curr. Opin. Pulm. Med. 2003, 9 (2), 111-6. (Pubitemid 36184561)
62. Shirali, G. S.; Ni, J.; Chinnock, R. E.; Johnston, J. K.; Rosenthal, G. L.; Bowles, N. E.; Towbin, J. A. Association of viral genome with graft loss in children after cardiac transplantation. N. Engl. J. Med. 2001, 344 (20), 1498-503. (Pubitemid 32429208)
63. Renton, K. W. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin. Drug Metab. Toxicol. 2005, 1 (4), 629-40.
64. Morgan, E. T.; Goralski, K. B.; Piquette-Miller, M.; Renton, K. W.; Robertson, G. R.; Chaluvadi, M. R.; Charles, K. A.; Clarke, S. J.; Kacevska, M.; Liddle, C.; Richardson, T. A.; Sharma, R.; Sinal, C. J. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab. Dispos. 2008, 36 (2), 205-16. (Pubitemid 351185732)
65. Baker, A. H.; McVey, J. H.; Waddington, S. N.; Di Paolo, N. C.; Shayakhmetov, D. M. The influence of blood on in vivo adenovirus bio-distribution and transduction. Mol. Ther. 2007, 15 (8), 1410-6. (Pubitemid 47099297)
66. Cichon, G.; Boeckh-Herwig, S.; Kuemin, D.; Hoffmann, C.; Schmidt, H. H.; Wehnes, E.; Haensch, W.; Schneider, U.; Eckhardt, U.; Burger, R.; Pring-Akerblom, P. Titer determination of Ad5 in blood: a cautionary note. Gene Ther. 2003, 10 (12), 1012-7. (Pubitemid 36722491)
67. Graham, M. L. Pegaspargase: a review of clinical studies. AdV. Drug DeliVery ReV. 2003, 55 (10), 1293-302. (Pubitemid 37464563)
68. Abuchowski, A.; van Es, T.; Palczuk, N. C.; McCoy, J. R.; Davis, F. F. Treatment of L5178Y tumor-bearing BDF1 mice with a nonimmunogenic L-glutaminase-L-asparaginase. Cancer Treat. Rep. 1979, 63 (6), 1127-32.
69. Hofherr, S. E.; Shashkova, E. V.; Weaver, E. A.; Khare, R.; Barry, M. A. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol. Ther. 2008, 16 (7), 1276-82. (Pubitemid 351866059)
70. Wonganan, P.; Croyle, M. A. PEGylated Adenoviruses: From Mice to Monkeys. Viruses 2010, 2 (2), 468-502.
71. Smith, T. A.; Idamakanti, N.; Marshall-Neff, J.; Rollence, M. L.; Wright, P.; Kaloss, M.; King, L.; Mech, C.; Dinges, L.; Iverson, W. O.; Sherer, A. D.; Markovits, J. E.; Lyons, R. M.; Kaleko, M.; Stevenson, S. C. Receptor interactions involved in adenoviralmediated gene delivery after systemic administration in non-human primates. Hum. Gene Ther. 2003, 14 (17), 1595-604. (Pubitemid 37452870)
72. Smith, T. A.; Idamakanti, N.; Rollence, M. L.; Marshall-Neff, J.; Kim, J.; Mulgrew, K.; Nemerow, G. R.; Kaleko, M.; Stevenson, S. C. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum. Gene Ther. 2003, 14 (8), 777-87. (Pubitemid 36623514)
73. Nicol, C. G.; Graham, D.; Miller, W. H.; White, S. J.; Smith, T. A.; Nicklin, S. A.; Stevenson, S. C.; Baker, A. H. Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol. Ther. 2004, 10 (2), 344-54. (Pubitemid 39117879)
74. Waddington, S. N.; McVey, J. H.; Bhella, D.; Parker, A. L.; Barker, K.; Atoda, H.; Pink, R.; Buckley, S. M.; Greig, J. A.; Denby, L.; Custers, J.; Morita, T.; Francischetti, I. M.; Monteiro, R. Q.; Barouch, D. H.; van Rooijen, N.; Napoli, C.; Havenga, M. J.; Nicklin, S. A.; Baker, A. H. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008, 132 (3), 397-409. (Pubitemid 351200513)
75. Kalyuzhniy, O.; Di Paolo, N. C.; Silvestry, M.; Hofherr, S. E.; Barry, M. A.; Stewart, P. L.; Shayakhmetov, D. M. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (14), 5483-8. (Pubitemid 351753889)
76. Hofherr, S. E.; Mok, H.; Gushiken, F. C.; Lopez, J. A.; Barry, M. A. Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum. Gene Ther. 2007, 18 (9), 837-48. (Pubitemid 47502849)
77. Tao, N.; Gao, G. P.; Parr, M.; Johnston, J.; Baradet, T.; Wilson, J. M.; Barsoum, J.; Fawell, S. E. In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice. Mol. Ther. 2001, 3 (1), 28-35.
78. Nunes, F. A.; Furth, E. E.; Wilson, J. M.; Raper, S. E. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum. Gene Ther. 1999, 10 (15), 2515-26. (Pubitemid 29489725)
79. Wolins, N.; Lozier, J.; Eggerman, T. L.; Jones, E.; Aguilar- Cordova, E.; Vostal, J. G. Intravenous administration of replication- incompetent adenovirus to rhesus monkeys induces thrombocytopenia by increasing in vivo platelet clearance. Br. J. Haematol. 2003, 123 (5), 903-5. (Pubitemid 37533303)
80. Varnavski, A. N.; Calcedo, R.; Bove, M.; Gao, G.; Wilson, J. M. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. Gene Ther. 2005, 12 (5), 427-36. (Pubitemid 40394295)
81. Zinkovsky, D. A.; Antonopoulos, M. S. Heparin-induced thrombocytopenia: overview and treatment. P. T. 2008, 33 (11), 642-51.